News
PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...
Formation Bio and Sanofi have several long-standing collaborations focused on identifying high-potential assets and co-developing AI tools that leverage shared data and technical expertise.
Sanofi, Formation Bio and OpenAI have jointly designed an AI-powered tool that will be rolled out in the former's phase 3 multiple sclerosis trials. There’s a new Muse in town.
AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi .
Formation Bio can fill that gap, with the capital, drug development capabilities, model, ... He led or co-led investments in Tidal Therapeutics (acquired by Sanofi for $160M upfront + $310M in ...
In May 2024, French pharmaceutical giant Sanofi announced a three-way collaboration with Formation Bio and OpenAI to develop AI software for drug research. William Tsai, Sanofi's Head of Public ...
Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results